報價延遲最少15分鐘:2026/04/22 03:20 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.03/-1.02
|
|
企業價值
442.90M
|
| 資產負債 |
|
每股賬面淨值
0.85
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. |
